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ABSTRACT
Biofilm production is an important mechanism for bacterial survival and its occurrence together 
with antimicrobial resistance represents a challenge for clinical management. Here, we evaluat-
ed the ability for biofilm production among P. aeruginosa isolates from patients with or without 
cystic fibrosis (CF) using two distinct media, besides determining the antimicrobial susceptibility 
profile of these isolates for eight antimicrobial agents. The ability for biofilm production when 
TSB medium was used was higher than when used CF sputum media (p = 0.0198). However, 
P. aeruginosa isolates from CF have demonstrated similar performance for biofilm production, in-
dependently of the medium used. Besides, among the biofilm-producing isolates, those recovered 
from CF were more resistant to the carbapenems (meropenem and imipenem) agents than those 
isolates from non-CF isolates.
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INTRODUCTION
Pseudomonas aeruginosa is one of the lead-
ing causes of nosocomial infections and it 
has a crucial role in cystic fibrosis (CF), being 
responsible for high level mortality and mor-
bidity.1,2 The lung of CF patients is character-
ized by high mucus production, which blocks 
clearance mechanisms. P. aeruginosa grows in 
CF lung as microcolonies promoting resistance 
to immunologic cells defense as well as persis-
tence character in face of nutritional deficiency 
and oxygen deprivation.3,4
It is well recognized that biofilm mode of 
growth can promote resistance to antimicro-
bial agents, and its occurrence in the infection 
process has been considered a limiting factor 
for therapeutic success.5,6 Moreover, there are 
just a few studies that evaluate biofilm produc-
tion on mucus and sputum in vitro and under 
these conditions one could expect better cor-
relation in vivo production. 
The aim of the present study was to com-
pare biofilm production among P. aerugi-
nosa isolates using tryptic soy broth (TSB), 
as conventional medium, and a pool of CF 
sputum, as alternative medium in microti-
ter plate assay. Besides, it was also compared 
the antimicrobial susceptibility profile of 
P. aeruginosa biofilm-producing isolates re-
covered from CF and non-CF patients against 
eight antimicrobial agents, using TSB medium.
MATERIAL AND METHODS
Samples and media
A total of 124 P. aeruginosa isolates, 52 from CF 
(PCF+) and 72 from non-CF (PCF-) patients, 
recovered form sputum and endotracheal aspi-
rates were evaluated.
Sputum specimens from randomly selected 
CF patients were collected into a sterile bot-
tle to prepare a pool of sputum. To certify the 
quality of the sputum, an amount of each speci-
men was stained by Gram and microscopically 
inspected (100x) using the presence of < 10 epi-
thelial cells per field as criterion. After, this pool 
was homogenized mechanically, autoclaved at 
121°C during 15 min and stored at -20°C. 
Biofilm formation
Quantitative determination of biofilm was 
made using a microtiter plate assay in accord-
ance with O’Toole et al.,7 with some modifi-
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cations. In brief, three to five colonies were suspended in 5 
mL of TSB and incubated overnight without shaking. After 
incubation, the stationary-phase culture was vortexed and 
thereafter diluted 1:100 in TSB with 0.25% glucose, 
and 200 μL of this solution was incubated in 96-well plates 
overnight at 35 ± 1°C. Media with suspended bacteria was 
then removed; the plates were carefully washed four times 
with water and air-dried before 200 μL of 0.9% crystal vio-
let solution (Sigma, Stockholm, Sweden) was added for 15 
min. After removing the dye solution and washing with wa-
ter, the attached dye was solubilized with 95% ethanol and 
the optical density of the adherent biofilm was determined 
dual with 450/630 nm microtiter plate reader (OrthoRead-
er II, Ortho diagnostic systems, New Jersey, USA). In the 
experiments, we have just used TSB with 0.25% glucose as 
a negative control (background absorbance). All isolates 
were tested at least three times in triplicate. For interpre-
tation of the results, the isolates were classified as follow: 
non-producing, weak, moderate, and strong-producing, 
based on the following optic density (OD) average values: 
OD (isolate) ≤ OD (control) = non-biofilm-producing; 
OD (control) ≤ OD (isolate) ≤ 2OD (control) = weak-
producing; 
2OD (control) ≤ OD (isolate) ≤ 4OD (control) = moder-
ate-producing;
4OD (control) ≤ OD (isolate) = strong-producing.8
Control strains
A reference biofilm-producing strain of Pseudomonas 
aeruginosa PAO1 and a non-producing strain of Pseu-
domonas aeruginosa ATCC 27853 were used as controls.
Antimicrobial susceptibility profile
Susceptibility profile to amikacin, aztreonam, cefepime, 
ceftazidime, ciprofloxacin, gentamicin, imipenem, mero-
penem and piperacillin-tazobactam was assessed by the 
VITEK automated system (bioMérieux, Marcy l`Étoile, 
France) using GNS-655 cards (bioMérieux, Marcy 
l`Étoile, France) in accordance with manufacturer’s in-
structions and breakpoints established by CLSI docu-
ments.9 The antimicrobial susceptibility profile of the bi-
ofilm producers was evaluated based on the TSB results.
Statistical analysis
Fisher’s exact test was used to compare biofilm produc-
tion by TSB and CF sputum media, as well as biofilm pro-
duction of cystic fibrosis and non-cystic fibrosis patients 
in sputum media. A p-value < 0.05 was considered statis-
tically significant.
RESULTS
Biofilm production
In TSB, 96.1% (50/52) of the PCF+ isolates have pro-
duced biofilm. Among PCF- isolates, 91.7% (66/72) have 
produced biofilm. A strong capacity to form biofilm has 
been observed in 56% (28/50) and in 39.4% (26/66) of the 
PCF+ and PCF- isolates, respectively. Using CF sputum, 
92.3% (48/52) of the PCF+ isolates showed to be biofilm-
producers and most of these were classified as moder-
ate biofilm-producers (58.3%). Among PCF- isolates, 
66.7% (48/72) were biofilm-producers and 46% (22/48) 
of these isolates were classified as strong biofilm-pro-
ducers (Table 1). The difference in the ability of produc-
ing biofilm between PCF- and PCF+ isolates, 66.7% vs 
92.3%, respectively, showed to be extremely significant 
(p = 0.0009).
Of the 52 PCF+ isolates that were evaluated using CF 
sputum, only two were unable to produce biofilm. However, 
our results showed that biofilm production using TSB was 
higher than when used CF sputum (p = 0.0198) (Table 1).
Biofilm production among Pseudomonas aeruginosa
Table 1. Biofilm production among P. aeruginosa isolates using two distinct media
 Source of the     Biofilm production in TS    Biofilm production in CF sputum
 isolates (nº) Non producer Weak Moderate Strong Non producer Weak Moderate Strong
 PCF+a (52) 2 6 16 28 4 8 28 12
 PCF-b (72) 6 14 26 26 24 12 14 22
 Subtotal (124) 8 20 42 54 28 20 42 34
 Total (124) 8*  116*  28*  96*
aPCF+, Pseudomonas aeruginosa from cystic fibrosis patients.
bPCF-, Pseudomonas aeruginosa from non-cystic fibrosis patients.
* Biofilm production considering TSB and CF sputum were statistically significant (p = 0.0198).
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Antimicrobial susceptibility profile and biofilm 
production
Table 2 illustrates the antimicrobial susceptibility profile 
of P. aeruginosa biofilm-producing from PCF+ and PCF-. 
Isolates with any degree of biofilm production (weak, 
moderate or strong) were considered as producer. Cipro-
floxacin was the least active antimicrobial agent against 
the panel of PCF+ isolates (48% resistant) followed by 
ceftazidime (40%) and aztreonam, cefepime and piper-
acillin-tazobactam (32%). A high proportion of PCF+ 
isolates displayed intermediate susceptibility to cefepime 
(40%). On the other hand, isolates from PCF- were more 
susceptible to piperacillin-tazobactam (81.8%) and 
more resistant to meropenem (63.6%). Eighteen PCF- 
isolates (25%) were susceptible to all eight antimicrobial 
agents tested. Interestingly, only six PCF+ isolates (11.5%) 
were susceptible to all eight antimicrobial agents tested.
DISCUSSION
The biofilm mode of growth is an important bacterial sur-
vival strategy. Pseudomonas aeruginosa can produce bio-
film in lungs of chronically infected cystic fibrosis patients, 
protecting the bacteria against antimicrobial agents and 
immune responses.10,11 Biofilm starts growing on a surface 
involving a complex mechanism of interaction between bac-
teria and environment. This interaction, usually started by 
a primary adhesion, is reversible during the first couple of 
hours; later the adhesion becomes irreversible due to pili and 
polysaccharides of the bacteria. Bacterial adherence to the 
airway components, such as epithelial cells and mucus, has 
been considered to be a first step for colonization and sub-
sequent establishment of an infection process.6 This mecha-
nism is still poorly understood and a lot of possibilities such 
as impermeability of the matrix and bacterial persistent cells 
probably contribute for this dynamic status. Also, biofilm 
production has been related to the occurrence of genetic 
events such as hypermutation, transfer of genes and acti-
vation of distinct metabolic pathways.5 It is described that 
P. aeruginosa can interact with elements like mucins, leci-
thin, eukaryotic DNA, salt, iron and other elements present 
in the mucus and contribute for the biofilm production.6 
In this study, we have evaluated the use of two me-
dia as vehicle to perform the test for biofilm production. 
Using a pool of CF sputum, isolates from 48 PCF+ and 
48 PCF- showed to be biofilm producing, while isolates 
from 4 PCF+ and 24 PCF- showed to be non-biofilm 
producing. Still, biofilm production in TSB was higher 
than in CF sputum (p = 0.0198). This can be explained by 
P. aeruginosa growing as microcolonies surrounded 
by matrix, mainly alginate, on sputum elements; in this 
condition is not observed the full adherence to the mi-
croplate well. On the other hand, the sputum can be a 
less rich medium than TSB to support biofilm production 
in both groups. But, interestingly, we have observed that 
PCF+ isolates maintained their ability of biofilm produc-
tion in both media. It is known that nutritionally rich 
conditions may be present in the CF airways, mainly ami-
no acids. This is the main fact that promotes auxotrophic 
isolates. Besides, in the secretions of these patients sub-
stances that freely circulate in the airway environment are 
generated, especially in chronic processes. This condition 
may promote a selection of P. aeruginosa isolates with 
higher capacity for biofilm production.3
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Table 2. Antimicrobial susceptibility profile of biofilm producers of cystic fibrosis patients vs. non-cystic fibro-
sis patients using TSB mediuma
 Antimicrobial  Cystic fibrosis patients (nb = 50) Non-cystic fibrosis patients (nb = 66)
 agents % susceptiblec % intermediatec % resistantc % susceptiblec % intermediatec % resistantc
 Amikacin 76 8 16 72.7 - 27.3
 Aztreonam 52 16 32 57.7 9 33.3
 Cefepime 28 40 32 30.3 24.2 45.5
 Ceftazidime 40 20 40 30.3 24.2 45.5
 Ciprofloxacin 52 - 48 54.5 - 45.5
 Gentamicin 48 28 24 63.6 - 36.4
 Imipenem 72 8 20 33.3 18.2 48.5
 Meropenem 92 - 8 36.4 - 63.6
 Piperacillin-tazobactam 68 - 32 81.8 - 18.2
aConsidering any degree of biofilm production (weak, moderate or strong).
bn is the total number of isolates with biofilm producer status.
cSusceptible, intermediate and resistant phenotypes, from CLSI breakpoints.
Braz J Infect Dis 2011; 15(4):301-304
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In this study, isolates with higher capacity to produce 
biofilm tended to have higher rates of resistance to the panel 
of antimicrobial agents tested, ranging from 86.6% (aztre-
onam) to 100% (amikacin) (data not shown). Delissalde and 
Amábile-Cuevas12 have reported in their study a rate slightly 
higher against six antimicrobials, ranging from 62% to 92% of 
biofilm production among resistant isolates after 24 h 
of incubation. The authors stated that multiresistant isolates 
had a higher capacity to produce biofilm both at 8 and 24 h 
of incubation. Interestingly, in this study the minority of 
P. aeruginosa isolates, not including isolates from CF, was 
capable of producing biofilm.12 In our study, of the 72 iso-
lates from PCF-, six (8.3%) were unable to produce biofilm 
in TSB. Among isolates from PCF+, only two isolates (3.8%) 
were unable to produce biofilm when we used TSB as me-
dium. On the other hand, 24 PCF-isolates were unable to 
produce biofilm when CF sputum was used as medium. 
Four isolates from PCF+ were unable to produce biofilm in 
CF sputum medium. Surprisingly, these four isolates were 
strong biofilm producers in TSB medium.
Knowledge of the susceptibility of P. aeruginosa to an-
timicrobial agents used for treatment not only serves as a 
guide to treatment for individual CF patients, but it is also 
valuable for identifying the prevalence of resistant strains 
within and among different treatment centers, given the mo-
bility of some patients. Our results have demonstrated that 
isolates from PCF+ and PCF- possess distinct profiles against 
a panel of antimicrobials. In particular, very high levels of 
resistance to two main drugs (meropenem and imipenem) 
were evident among isolates from PCF-, casting doubt on 
the adequacy of their empirical use in this patient group. 
This difference between the susceptibility profiles can be ex-
plained by the nature of the infection, since isolates from 
PCF- were recovered from patients admitted in the intensive 
care unit, nosocomial setting with a great selective pressure 
for extended spectrum antimicrobials such as carbapenems. 
In fact, our results showed that isolates from PCF- displayed 
more resistance to carbapenems than isolates from PCF+. 
Surprisingly, susceptibility to all eight antimicrobial agents 
was higher among isolates from PCF- than isolates from 
PCF+ (25% vs 11.5%).
Invariably, these isolates were able to produce biofilm in 
distinct media. Although biofilm production has recently 
been studied more deeply, more studies are still needed to 
improve our understanding about the link between viru-
lence factors and antimicrobial resistance.
We are aware of the fact that CF sputum medium used 
here is not entirely representative of CF lung environment 
because other active compounds and growth conditions, 
including anaerobic atmosphere, may be also present.4,6 On 
the other hand, P. aeruginosa isolates from PCF+ apparently 
displayed, under distinct conditions, the same feature for the 
biofilm production.
Biofilm production among Pseudomonas aeruginosa
Biofilm production and antimicrobial resistance are 
among the main bacterial defense apparatus during an in-
fectious process, and both represent currently a great chal-
lenge to the therapeutic practice.
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